Instrument Inactif

Communiqués Versartis Inc Nasdaq

Actions

US92529L1026

Recherche biotechnologique et médicale

Communiqués

17/01/24	Aravive, Inc. to Delist from The Nasdaq Stock Market	AQ
02/08/23	Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer	AQ
28/07/23	Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023	AQ
14/07/23	Aravive to Participate in William Blair’s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023	AQ
13/06/23	Aravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)	AQ
05/06/23	ARAVIVE, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
05/06/23	Aravive To Participate in the Jefferies Global Healthcare Conference	AQ
25/05/23	ARAVIVE, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
25/05/23	Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023	AQ
16/05/23	Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma	AQ
10/05/23	Aravive: Q1 Earnings Snapshot	AQ
10/05/23	Aravive Reports First Quarter 2023 Financial Results and Provides Corporate Updates	AQ
08/05/23	Aravive to Host Virtual KOL Event on its Late-Stage Oncology Asset Batiraxcept	AQ
26/04/23	Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting	AQ
11/04/23	ARAVIVE, INC. : Unregistered Sale of Equity Securities, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
11/04/23	Aravive Appoints Carolina Petrini as Chief Commercial Officer	AQ
15/03/23	Aravive: Q4 Earnings Snapshot	AQ
15/03/23	ARAVIVE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
15/03/23	Aravive Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates	AQ
28/02/23	ARAVIVE, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
28/02/23	Aravive Announces FDA Orphan Drug Designation Granted to Batiraxcept for the Treatment of Pancreatic Cancer	AQ
13/02/23	ARAVIVE, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
13/02/23	Aravive to Present Positive Updated Data from Phase 1b Trial of Batiraxcept in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma at the 2023 ASCO Genitourinary (GU) Cancers Symposium	AQ
06/02/23	ARAVIVE, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
18/01/23	ARAVIVE, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	AQ